Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 10 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 10 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 IN PLASTIC CONTAINER.
AMINOSYN II 10% IN PLASTIC CONTAINER vs AMINOSYN II 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 10% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis, maintenance of nitrogen balance, and tissue repair in parenteral nutrition.
Aminosyn II 3.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis and maintenance of nitrogen balance. The amino acids serve as substrates for protein synthesis, and their metabolism yields nitrogen for ureagenesis and carbon skeletons for gluconeogenesis or oxidation.
Intravenous infusion: 7-12 g amino acids per kg body weight per day (0.7-1.2 g/kg/day) for adults with normal renal function; typically administered as a 10% solution at a rate not exceeding 0.5 g amino acids/kg/hour.
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour (equivalent to 0.035-0.07 g amino acids/kg/hour) for protein supplementation, not to exceed 0.2 g nitrogen/kg/day. Dosage individualized based on metabolic needs and clinical response.
None Documented
None Documented
Variable depending on individual amino acids; typical of infused amino acids: 0.5-2 hours for most, with clinical context of continuous infusion achieving steady-state within 24 hours.
The terminal elimination half-life of infused amino acids is not typically defined as a single value because they are rapidly cleared from plasma for protein synthesis and metabolic processes. For labeled amino acids, the plasma clearance half-life ranges from 10-30 minutes. Clinically, the half-life is short; continuous infusion is required to maintain plasma amino acid levels. In patients with hepatic or renal dysfunction, half-life may be prolonged.
Amino acids are metabolized; excess nitrogen is excreted renally as urea (70-90%) and to a lesser extent in feces (5-10%).
Aminosyn II 3.5% is a crystalline amino acid solution. The amino acids are metabolized and utilized for protein synthesis. Excess nitrogen is converted to urea in the liver and excreted renally as urea. Approximately 80-90% of infused amino acids are incorporated into proteins or metabolized; the remainder is excreted in urine as urea and other nitrogenous wastes. Fecal excretion is negligible (less than 2%) as amino acids are not significantly eliminated in bile. In patients with renal impairment, urea excretion is decreased, leading to azotemia.
Category C
Category C
Amino Acid Solution
Amino Acid Solution